Cyanoacrylate Embolization: A Novelty in the Field of Varicose Veins Surgery

In the past 2 decades, varicose veins surgery went through a great turbulence and various innovations. A number of new techniques have been introduced with a goal to increase the success rate, reduce the periprocedural complications and, overall, to improve patients' quality of life. The latest of them, named cyanoacrylate embolization (CAE) technique, threatens to shake the glory of the currently well-established endovenous methods. We have analyzed all previous studies by searching MEDLINE base using PubMed. Although the idea of using n-butyl cyanoacrylate (NBCA) glue in medical purposes was not new, the very first in vivo and animal experiments using NBCA for vein closure were conducted just at the beginning of this millennium. The results of these studies gave warranty to begin with the first interventions in humans. Early studies reported very high success rates of more than 90%, with the longest follow-up period of 36 months. There were no major adverse events reported, while the minor ones—mostly phlebitic reactions—were defined as mild to moderate. The newest head-to-head studies showed that CAE is a noninferior technique to other endovenous methods, with higher occlusion rates and fewer adverse events. Short procedure time and no need for tumescent anesthesia or compressive stockings reduce patients' discomfort to the minimum and definitely seem to be a step forward answering the modern “walk in–walk out surgery” demands. As an easily handling technique, CAE undoubtedly pierces its path to the top of varicose veins surgery but more head-to-head clinical trials with longer follow-up periods are necessary to obtain a plain picture.